在动脉高血压中使用RNA向疗法
Egidio Imbalzano1, Riccardo M Inciardi2, Luana Orlando1
1Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
European heart journal. Quality of care & clinical outcomes
|October 22, 2025
概括
以RNA为向的疗法,包括小干扰RNA (siRNA) 和反感性寡核酸 (ASO),在治疗高血压,特别是耐药病例方面表现有前途. 这些新的治疗方法有可能改善坚持和长期控制血压.
科学领域:
- 心血管医学 心血管医学
- 药物基因组学 药物基因组学
- 在RNA疗法方面.
背景情况:
- 高血压影响全球数百万人,许多患者因耐药性或不良坚持而对当前治疗无反应.
- 抗性高血压和复杂的并发症需要创新的治疗策略.
- 向RNA的治疗方法为高血压管理提供了一种精准医学方法.
研究的目的:
- 审查RNA向核酸治疗高血压的安全性和有效性.
- 探索新型治疗方法,如针对血管新生素合成的zilebesiran和IONIS-AGT-LRX.
- 评估基于RNA的药物作为传统抗高血压药物的长效替代品的潜力.
主要方法:
- 对高血压的RNA向治疗药物的临床前和临床试验的审查.
- 对小干扰RNA (siRNA) 和反感性寡核酸 (ASO) 的安全性和有效性数据的分析.
- 检查作用机制,包括向肝脏血管酶原体的合成.
主要成果:
- 基于RNA的药物,如zilebesiran和IONIS-AGT-LRX,在向AGT mRNA和降低血管激素水平方面表现出潜在的潜力.
- 皮下RNA注射提供了诸如目标特异性和长时间作用等优势.
- 目前证据有限,临床前和临床阶段的研究正在进行中.
结论:
- 向RNA的疗法代表了高血压管理的有希望的途径,特别是对于耐药性疾病或合规问题患者.
- 需要进一步的研究来确定长期的心血管结果,目标器官保护和死亡率的好处.
- 这些疗法不适合高血压紧急情况,需要更广泛的临床验证.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
411
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
411
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
414
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
414
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K